跳至主要内容
临床试验/CTRI/2011/12/002235
CTRI/2011/12/002235已完成未知

An open-label, randomized, single-dose, crossover studyto evaluate the relative bioavailability of two 150 mgaliskiren MR (modified release) microparticle formulations(capsule) vs. marketed 150mg tablet in healthy adultvolunteers

ovartis Healthcare Private Limited0 个研究点目标入组 42 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ba/be

入排标准

入选标准

  • 1. Healthy Subjects
  • 2. Female subejcts must be of non-child bearing potential
  • 3. Subjects must weigh at least 50kg & their BMI 18 to 30 kg/m2 for participation

排除标准

  • 1. Smokers
  • 2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
  • 3. Pregnant or nursing (lactating) women
  • 4. Impaired hepatic or relnal function test results
  • 5. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result

研究者

发起方
ovartis Healthcare Private Limited

相似试验